Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.
Company Info
Funding & Investor Relations
N/A (Roche is the ultimate parent; fully acquired in 2009 for $46.8B)
Upcoming Milestones & Key Dates
Q1 2026 Earnings (Roche Group) — Genentech restructuring update
Completion of infectious disease unit wind-down
Clinical Development Pipeline
Recent News
An Endpoints News exclusive: Genentech is closing its infectious disease research unit and laying off longtime top scientist Vishva Dixit as part of a broader R&D restructuring that will affect hundreds of roles in South San Francisco.
Genentech is laying off R&D staff including a top executive who had been with the Roche subsidiary for nearly 30 years, as part of a broader restructuring that is also closing some research units.
Genentech's ongoing R&D restructuring has now reached the VP level, with three senior vice presidents among those dismissed in the latest wave, including longtime infectious disease research leader Vishva Dixit.
Genentech, a Roche subsidiary, has laid off its top infectious disease scientist Dr. Vishva Dixit and is closing its infectious disease research unit as part of a broader R&D restructuring. The move signals a strategic pullback from anti-infective drug development.
Leadership Team
Careers & Job Openings